Cambium Bio Secures US, Australia Ethical Approval for Phase Three Eye Disease Treatment Candidate Trial

MT Newswires Live06-30

Cambium Bio (ASX:CMB) secured ethics approval to begin its registration-enabling phase three clinical trials of Elate Ocular treatment candidate for the treatment of moderate to severe dry eye disease in both Australia and the US, according to a Monday Australian bourse filing.

The ethics approval in Australia was granted by Bellberry Human Research Ethics Committee on June 26, while the approval in the US was granted by Advarra Institutional Review Board on May 9.

The first patient dosing is anticipated in October, and it will randomize around 800 patients globally. The co-primary endpoints include improvement in total corneal fluorescein staining and eye discomfort VAS score, relating to dry eye disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2547424052?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 15:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547424052","market":"hk","top_or_hot":-1,"title":"Cambium Bio Secures US, Australia Ethical Approval for Phase Three Eye Disease Treatment Candidate Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CMB.AU\">Cambium Bio</a> (ASX:CMB) secured ethics approval to begin its registration-enabling phase three clinical trials of Elate Ocular treatment candidate for the treatment of moderate to severe dry eye disease in both Australia and the US, according to a Monday Australian bourse filing.</p><p>The ethics approval in Australia was granted by Bellberry Human Research Ethics Committee on June 26, while the approval in the US was granted by Advarra Institutional Review Board on May 9.</p><p>The first patient dosing is anticipated in October, and it will randomize around 800 patients globally. The co-primary endpoints include improvement in total corneal fluorescein staining and eye discomfort VAS score, relating to dry eye disease.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cambium Bio Secures US, Australia Ethical Approval for Phase Three Eye Disease Treatment Candidate Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCambium Bio Secures US, Australia Ethical Approval for Phase Three Eye Disease Treatment Candidate Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-30 15:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CMB.AU\">Cambium Bio</a> (ASX:CMB) secured ethics approval to begin its registration-enabling phase three clinical trials of Elate Ocular treatment candidate for the treatment of moderate to severe dry eye disease in both Australia and the US, according to a Monday Australian bourse filing.</p><p>The ethics approval in Australia was granted by Bellberry Human Research Ethics Committee on June 26, while the approval in the US was granted by Advarra Institutional Review Board on May 9.</p><p>The first patient dosing is anticipated in October, and it will randomize around 800 patients globally. The co-primary endpoints include improvement in total corneal fluorescein staining and eye discomfort VAS score, relating to dry eye disease.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XJO.AU","symbol_name":"标普/澳交所 200指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2547424052","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547424052","pubTimestamp":1751267960,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cambium Bio  secured ethics approval to begin its registration-enabling phase three clinical trials of Elate Ocular treatment candidate for the treatment of moderate to severe dry eye disease in both Australia and the US, according to a Monday Australian bourse filing.The ethics approval in Australia was granted by Bellberry Human Research Ethics Committee on June 26, while the approval in the US was granted by Advarra Institutional Review Board on May 9.The first patient dosing is anticipated in October, and it will randomize around 800 patients globally. The co-primary endpoints include improvement in total corneal fluorescein staining and eye discomfort VAS score, relating to dry eye disease.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XJO.AU":"标普/澳交所 200指数","CMB.AU":"Cambium Bio Limited","BK7067":"生物科技","XAO.AU":"标普/澳交所 普通股指数","XKO.AU":"标普/澳交所 300指数"},"translate_title":"Cambium Bio获得美国和澳大利亚三期眼病治疗候选试验的伦理批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":1,"XJO.AU":1,"CMB.AU":0.9,"XAO.AU":1},"content_text":"Cambium Bio (ASX:CMB) secured ethics approval to begin its registration-enabling phase three clinical trials of Elate Ocular treatment candidate for the treatment of moderate to severe dry eye disease in both Australia and the US, according to a Monday Australian bourse filing.The ethics approval in Australia was granted by Bellberry Human Research Ethics Committee on June 26, while the approval in the US was granted by Advarra Institutional Review Board on May 9.The first patient dosing is anticipated in October, and it will randomize around 800 patients globally. The co-primary endpoints include improvement in total corneal fluorescein staining and eye discomfort VAS score, relating to dry eye disease.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2547424052","isCrawlerRequest":true}